Acura and King receive letter
PALATINE - Acura Pharmaceuticals Inc. and King Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the new drug application for Acurox Tablets CII, a product intended for the relief of moderate-to-severe pain. The letter raises issues regarding the potential abuse deterrent benefits of Acurox. Acura, with offices in Palatine, and King said that at this stage, say they believe they can respond to the issues raised without conducting any additional studies.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.